6 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Within triple-negative breast cancer, MSL is a historical RNA label with a substantial stromal contribution. TNBCtype-4 reassigned these cases using expression correlations; it did not automatically turn every MSL call into mesenchymal cancer.
The 2011 TNBCtype system included a mesenchymal stem-like profile with lower proliferation-related expression and mesenchymal/stem-like programmes. In the 2016 study, paired laser-capture analyses of epithelial-enriched and stromal regions showed a strong stromal contribution to this signal.
TNBCtype-4 removed IM and MSL as separate tumour-focused labels and reassigned those samples to their second-highest correlated tumour-profile centroid. MSL was not simply renamed M, and a whole-tissue call does not prove that only stromal cells contributed. Immune and stromal signals remain useful context. Claudin-low is another phenotype with its own classifier and cannot be inferred from an MSL name alone.
| Setting | Approach | Guideline |
|---|---|---|
| Any stage | As for triple-negative disease; the label has no treatment consequence. | not mapped |